Citations

Showing 10 of 108094 citations.

Concomitant presentation of eosinophilic or oncocytic mucoepidermoid carcinoma, immunoglobulin G4–related disease, and adult-onset asthma and periocular xanthogranuloma: Case report of 3 uncommon clinical entities
Cebak, John E., Schmitt, Alessandra C. , Thorwarth, Ryan, Rodríguez-Pla, Alicia , Schmitt, Alessandra, Rosenthal, Allison C, Taylor, Cullen M. , Thorwarth, Ryan M, Rodriguez-Pla, Alicia , Chhabra, Nikita , Lal, Devyani , Rosenthal, Allison , Shah, Ami A.

Mayo Clinic

Medicine | August 12, 2022 | Volume: 101 | Issue: 32 | Pages: e30067

10.1097/md.0000000000030067 | PMID 35960078 Get It

Rationale: Immunoglobulin (Ig) G4–related disease (IgG4-RD) reportedly has a strong relationship with adult-onset asthma and periocular xanthogranuloma (AAPOX) and may be linked to sclerosing mucoepidermoid carcinoma (MEC). We present a rare case of IgG4-RD and AAPOX occurring in a patient with resected eosinophilic or oncocytic MEC. Patient concerns: A 52-year-old woman was referred to our rheumatology clinic in 2020 to be evaluated for suspected IgG4-RD. Diagnoses: The patient had diagnoses of periorbital xanthelasmas, worsening glucocorticoid-dependent chronic rhinosinusitis and adult-onset asthma, and cervical lymphadenopathy persisting 2 years after resection of a low-grade MEC of a minor salivary gland. Interventions: Because the patient’s symptomatic relief was glucocorticoid dependent, IgG4-RD was suspected, and she was referred to our medical center. Her amylase and lipase levels were elevated. Serum IgG4 levels were initially within normal limits, but IgG4-RD was diagnosed because of the presence of lymphadenopathy and evidence of pancreatitis, which was shown on positron emission tomography/computed tomography. Furthermore, the IgG4 levels later increased without explanation. After the patient began combination therapy with a glucocorticoid (prednisone) and methotrexate, her symptoms improved but recurred when the daily oral glucocorticoid dosage decreased below 10 mg. An excisional biopsy of her right submandibular gland in 2021 yielded results consistent with IgG4-RD. In addition, AAPOX was diagnosed, given the presence of periocular edema and plaques, adult-onset asthma, and rhinosinusitis. Outcome: The patient was carcinoma free at last follow-up and was receiving medication to treat the other conditions. Lessons: The diagnosis of these 3 concomitant, uncommon entities required approximately 7 years of medical investigations. Clinicians should know that IgG4-RD, AAPOX, and MEC may occur together.
Amelioration of Leigh syndrome induced by mouse blastocyst complementation with a mutant human mitochondrial ATP synthase 6
Yuan, Huijun , Bhatti, Muhammad Tariq, Guy, John, Webster, Keith A. , Bhatti, Muhammad Tariq, Hauswirth, William W. , Lewin, Alfred S.

Mayo Clinic

Clinical and Translational Discovery | August 12, 2022 | Volume: 2 | Issue: 3 | Pages: No page available

10.1002/ctd2.114 Get It

AbstractBackgroundMutation of the m. 8993 T > G ATP6 subunit of ATP synthase causes a maternally inherited Leigh Syndrome (LS), a rapidly fatal encephalomyelopathy in childhood called and related Neuropathy, Ataxia and Retinitis Pigmentosa (NARP) in adults. There is no cure, and relevant animal models are few. Here we describe a novel ATP6 mouse model of LS and preclinical efficacy of a gene therapy approach to neutralize the ATP6 mutation by competition with a mitochondrial targeted adeno‐associated virus serotype 9 (AAV9) vector containing wild‐type ATP6.MethodsLS transgenic mice with an ATP6 mutation were developed by microinjecting AAV2 modified by a COX8 mitochondrial targeting sequence (MTS) into mouse blastocysts to deliver the human ATP6 gene with a T > G mutation at position 8993 of the mitochondrial genome, responsible for clinical LS DNA, protein, and metabolic assays confirmed functional gene delivery and in depth physiological/clinical assessments supported germline transmission of an LS phenotype. Rescue of LS in this model was evaluated after intravenous injection of mito‐targeted AAV9 containing wild‐type ATP6 followed by reevaluation of phenotypes.ResultsLS transgenic mice expressed mutant ATP6 protein in multiple relevant tissues including brain, eye, liver. Mutant ATP6 incorporated into Complex V and conferred decreased ATP synthase efficiency. Mice exhibited hallmarks of the human disease with one or multiple systemic symptoms including early death, paralysis, hunching, vision loss and seizures over six generations. Necropsy revealed spongiform encephalopathy, retinal degeneration, and cardiomegaly. Rescue by mitochondrially directed AAV9 containing wild type ATP6 after disease onset conferred prolonged survival and reduced paralysis. When administered prior to disease onset all treated ATP6 mice survived with evidence of globally improved function.ConclusionsThe results are consistent with efficient delivery and expression of foreign genes in mitochondria by AAV vectors directed by MTS and support further development of such strategies via intravenous injection of mitochondrial targeted AAV9 to deliver corrective genes.
Breast cancer‐related lymphedema correlated with incidence of cellulitis and mortality
Cheng, Ming‐Huei , Ho, Olivia A. , Tsai, Tai‐Jung, Lin, Yi‐Ling , Ho, Olivia A , Kuo, Chang‐Fu

Mayo Clinic

Journal of Surgical Oncology | August 12, 2022 | Volume: 126 | Issue: 7 | Pages: 1162-1168

10.1002/jso.27054 | PMID 35960614 Get It

Abstract Background This study investigated breast cancer‐related lymphedema (BCRL) and its correlation with the incidence of cellulitis and mortality in the National Health Insurance (NHI) database in Taiwan. Methods Between 2004 and 2014, the NHI database of patients with breast cancer who underwent surgical procedures, adjuvant therapies, BCRL, cellulitis, and mortality were retrospectively reviewed. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of BCRL and cellulitis in different treatment groups. The associations of BCRL with the incidence of cellulitis and mortality were further analyzed using the Kaplan–Meier curve. Results Among 100 301 patients, 5464 (5.4%) developed BCRL with a median onset of 1.3 years. At a mean follow‐up of 4.77 years, the incidence of cellulitis in the BCRL group (12.7%, 694/5464 patients) was significantly higher than in the no‐BCRL group (2.73%, 2589/94 837 patients) (HR: 3.74; 95% CI: 3.43–4.08; p < 0.0001). At a mean follow‐up of 5.77 years, the mortality rate in the cellulitis group (34.21%, 1123/3283 patients) was significantly greater than in the no‐cellulitis group (16.29%, 15 804/97 018 patients) (HR: 1.17; 95% CI: 1.1–1.24; p < 0.0001). Conclusions BCRL had a significantly higher incidence of cellulitis and mortality.
The RET Inhibitor Selpercatinib May Cause Hypothyroidism by Inhibiting Type 2 Iodothyronine Deiodinase
Kotwal, Anupam , Morris, John C. , Morris, John C.

Mayo Clinic

Clinical Thyroidology | August 12, 2022 | Volume: 34 | Issue: 8 | Pages: 361-364

10.1089/ct.2022;34.361-364 Get It

Is Thyroglobulin a Useful Marker in the Monitoring of Differentiated Thyroid Cancer Following Lobectomy or Without Radioactive Iodine?
Solís-Pazmiño, Paola , Brito, Juan P.

Mayo Clinic

Clinical Thyroidology | August 12, 2022 | Volume: 34 | Issue: 8 | Pages: 355-357

10.1089/ct.2022;34.355-357 Get It

Spontaneous Regression of Metastatic Lung Adenocarcinoma Following a Core Biopsy
Samhouri, Bilal F. , Edell, Eric S. , Dimou, Anastasios , Boland, Jennifer M.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | August 12, 2022 | Volume: 30 | Issue: 2 | Pages: 181-184

10.1097/lbr.0000000000000867 | PMID 35959896 Get It

Radiation-induced Airway Disease
Hernandez‐Rojas, Daniel , Lee‐Mateus, Alejandra Yu , Khoór, András , Rojas, Carlos A. , Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra , Abia‐Trujillo, David

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | August 12, 2022 | Volume: 30 | Issue: 2 | Pages: 184-187

10.1097/lbr.0000000000000868 | PMID 35959893 Get It

Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis
Yao, Liang , Li, Jing , Li, Meixuan , Lin, Clement , Xu, Hui , Tamilselvan, Divyalakshmi , Kandi, Maryam , Sreekanta, Ashwini , Makhdami, Nima , Ali, Dalal S. , Dandurand, Karel , Yang, Kehu , Bilezikian, John P. , Mannstadt, Michael , Khan, Aliya , Hui, Xu , Brandi, Maria Luisa , Clarke, Bart L , Mannstadt, Michael , Rejnmark, Lars , Khan, Aliya A , Guyatt, Gordon , Tamilselvan, Divya , Brandi, Maria Luisa , Clarke, B.L. , Rejnmark, Lars , Guyatt, Gordon

Mayo Clinic

Journal of Bone and Mineral Research | August 12, 2022 | Volume: 37 | Issue: 12 | Pages: 2654-2662

10.1002/jbmr.4676 | PMID 36385517 Get It

ABSTRACT The efficacy and safety of parathyroid hormone (PTH) therapy for managing long-term hypoparathyroidism is being evaluated in ongoing clinical trials. We undertook a systematic review and meta-analysis of currently available randomized controlled trials to investigate the benefits and harms of PTH therapy and conventional therapy in the management of patients with chronic hypoparathyroidism. To identify eligible studies, published in English, we searched Embase, PubMed, and Cochrane CENTRAL from inception to May 2022. Two reviewers independently extracted data and assessed the risk of bias. We defined patients' important outcomes and used grading of recommendations, assessment, development, and evaluation (GRADE) to provide the structure for quantifying absolute effects and rating the quality of evidence. Seven randomized trials of 12 publications that enrolled a total of 386 patients proved eligible. The follow-up duration ranged from 1 to 36 months. Compared with conventional therapy, PTH therapy probably achieves a small improvement in physical health-related quality of life (mean difference [MD] 3.4, 95% confidence interval [CI] 1.5–5.3, minimally important difference 3.0, moderate certainty). PTH therapy results in more patients reaching 50% or greater reduction in the dose of active vitamin D and calcium (relative risk [RR] = 6.5, 95% CI 2.5–16.4, 385 more per 1000 patients, high certainty). PTH therapy may increase hypercalcemia (RR =2.4, 95% CI 1.2–5.04, low certainty). The findings may support the use of PTH therapy in patients with chronic hypoparathyroidism. Because of limitations of short duration and small sample size, evidence from randomized trials is limited regarding important benefits of PTH therapy compared with conventional therapy. Establishing such benefits will require further studies. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry
Daimee, Usama A. , Wang, Yongfei , Masoudi, Frederick A. , Varosy, Paul D. , Du, Chengan, Koutras, Cristina, Saw, Jacqueline , Price, Matthew J. , Curtis, Jeptha P. , Reddy, Vivek Y , Saw, Jacqueline , Price, Matthew J , Kusumoto, Fred M , Curtis, Jeptha P , Freeman, James V , Friedman, Daniel J , Reddy, Vivek Y. , Kusumoto, Fred , Freeman, James V.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 12, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.121.008418 | PMID 35959677 Get It

Background: The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device for patients who are at increased stroke risk and are suitable for oral anticoagulation but who have an appropriate reason to seek a nondrug alternative. These broad criteria raise the question of their interpretation in clinical practice. There is a lack of studies comprehensively evaluating the indications for Watchman implantation among a large series of patients from contemporary, real-world practice in the United States. Methods: We used the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry to identify Watchman procedures performed between 2016 and 2018. We assessed procedural indications for Watchman implantation in the United States and evaluated the association between procedural indications and in-hospital adverse events. Results: A total of 38 314 procedures were included. The mean patient age was 76.1±8.1 years, and 58.9% were men. The mean CHA 2 DS 2 -VASc score was 4.8±1.5, whereas the mean hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) score was 3.0±1.1. Prior stroke or transient ischemic attack was reported in 40.2% and prior bleeding in 70.1%, with gastrointestinal bleeding being most common (41.9%). The most common site-reported procedural indications for Watchman implantation were increased thromboembolic risk (64.8%) and history of major bleed (64.3%), followed by high fall risk (35.5%). Most (71.9%) had ≥2 procedural indications. Patients with high fall risk had increased risk of in-hospital adverse events (adjusted OR, 1.12; P =0.025), but no other differences were found in the risk of in-hospital adverse events by procedural indication. Conclusions: Among patients in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common procedural indications for Watchman implantation were increased thromboembolic risk, history of major bleed, and high fall risk. A majority of patients had multiple procedural indications. High fall risk conferred a modestly increased risk of in-hospital adverse events.
DNASE-MEDIATED DISSOLUTION OF NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATES IN VITRO THROMBIN GENERATION KINETICS IN TRAUMA PATIENTS
Goswami, Julie , Mahony, C , Kizhakkedathu, Jayachandran N. , Vappala, Sreeparna , Morrissey, James H. , Spears, Grant M. , Bailey, Kent R. , Dong, Jing‐fei , Kozar, Rosemary A. , Hall, Nathan W , Johnstone, Andrea L. , Park, Myung S., MacArthur, Taleen A. , Mahony, Cillian, Smith, Stephanie A.

Mayo Clinic

Shock | August 12, 2022 | Volume: 58 | Issue: 3 | Pages: 217-223

10.1097/shk.0000000000001972 | PMID 35959777 Get It

ABSTRACT Introduction: Neutrophil extracellular traps (NETs) trigger thrombin generation. We aimed to characterize the effects of deoxyribonuclease (DNAse) on NET components (cell-free DNA [cfDNA] and histones) and thrombin generation after trauma. Methods: Citrated plasma samples were collected from trauma patients and healthy volunteers. Thrombin generation (calibrated automated thrombogram) was measured as lag time (LT, in minutes), peak height (in nM), and time to peak thrombin generation (in minutes). Citrullinated histone 3 (CitH3) and 4 (CitH4) were measured by enzyme-linked immunosorbent assay; cfDNA by PicoGreen (all in nanograms per milliliter). Samples analyzed +/− DNAse (1,000 U/mL). Results expressed as median and quartiles [Q1, Q3], Wilcoxon testing, P < 0.05 significant. Results: We enrolled 46 patients (age, 48 [31, 67] years; 67% male) and 21 volunteers (age, 45 [28, 53] years; 43% male). Deoxyribonuclease treatment of trauma plasma led to shorter LT (3.11 [2.67, 3.52] min; 2.93 [2.67, 3.19] min), shorter time to peak thrombin generation (6.00 [5.30, 6.67] min; 5.48 [5.00, 6.00] min), greater peak height (273.7 [230.7, 300.5] nM; 288.7 [257.6, 319.2] nM), decreased cfDNA (576.9 [503.3, 803.1] ng/mL; 456.0 [393.5, 626.7] ng/mL), decreased CitH3 (4.54 [2.23, 10.01] ng/mL; 3.59 [1.93, 7.98] ng/mL), and increased H4 (1.30 [0.64, 6.36] ng/mL; 1.75 [0.83, 9.67] ng/mL), all P < 0.001. The effect of DNAse was greater on trauma patients as compared with volunteers for LT (ΔLT, −0.21 vs. −0.02 min, P = 0.007), cfDNA (ΔcfDNA −133.4 vs. −84.9 ng/mL, P < 0.001), and CitH3 (ΔCitH3, –0.65 vs. −0.11 ng/mL, P = 0.004). Conclusion: Deoxyribonuclease treatment accelerates thrombin generation kinetics in trauma patient samples as compared with healthy volunteers. These findings suggest that NETs may contribute to the hypercoagulable state observed in trauma patients.